Unternehmen NuGenerex Immuno-Oncology, Inc.
Aktien
A2P853
US67053X1028
NUGX
Biotechnologie
Kurzporträt
Mitarbeiterzahl: 6
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joseph Moscato
CEO | Chief Executive Officer | 61 | 01.01.17 |
Mark Corrao
DFI | Director of Finance/CFO | 67 | - |
Eric von Hofe
PSD | President | 66 | - |
Jason Terrell
CTO | Chief Tech/Sci/R&D Officer | 43 | - |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 18.01.17 |
Director/Board Member | 54 | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Marvin Hausman
BRD | Director/Board Member | 82 | - |
Brian T. McGee
BRD | Director/Board Member | 63 | - |
Carol A. Nacy
BRD | Director/Board Member | 76 | - |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 18.01.17 |
Craig Eagle
BRD | Director/Board Member | 57 | - |
Joseph Moscato
CEO | Chief Executive Officer | 61 | 01.01.17 |
Director/Board Member | 54 | - | |
Thomas Leonard
BRD | Director/Board Member | 50 | - |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 101 196 670 | 33 149 554 ( 32,76 %) | 0 | 32,76 % |
Unternehmenskontakt
NuGenerex Immuno-Oncology, Inc.
10102 USA Today Way Suite 200
33025, Miramar
+(416) 364-2551
http://www.nugenerexio.comSektor
% 1. Jan. | Kap. | |
---|---|---|
-2,31 % | 103 Mrd. | |
+0,56 % | 95,28 Mrd. | |
+1,69 % | 22,15 Mrd. | |
-17,37 % | 21,02 Mrd. | |
-9,30 % | 18,15 Mrd. | |
-41,01 % | 16,73 Mrd. | |
-14,85 % | 16,05 Mrd. | |
+3,21 % | 13,68 Mrd. | |
+33,54 % | 12,17 Mrd. |